论文部分内容阅读
目的探讨血清肿瘤标志物CYFRA21-1检测原发性肝癌(primary hepatic cancer,PHC)的诊断价值。方法2003年7月至2007年12月收治的330例肝病患者,其中组织病理学诊断为原发性肝癌者192例,非原发性肝癌者138例。采用电化学发光免疫分析法对330例肝病患者的血清CYFRA21-1水平进行检测。结果血清CYFRA21-1水平PHC组为(9.73±1.02)ng/mL,非PHC患者为(1.33±0.26)ng/mL,两组间差异具有统计学意义(P<0.01),不同组织学分型的PHC患者血清CYFRA21-1水平之间的差异也具有统计学意义(P<0.01)。结论检测血清中CYFRA21-1水平对HPC的诊断有一定的指导意义。
Objective To investigate the diagnostic value of serum tumor marker CYFRA21-1 in detecting primary hepatic cancer (PHC). Methods From July 2003 to December 2007, 330 cases of liver disease were treated, of which 192 cases were diagnosed as primary liver cancer by histopathology and 138 cases were non-primary liver cancer. Electrochemiluminescence immunoassay was used to detect serum CYFRA21-1 levels in 330 patients with liver disease. Results The serum level of CYFRA21-1 in PHC group was (9.73 ± 1.02) ng / mL and in non-PHC group was (1.33 ± 0.26) ng / mL, the difference was statistically significant (P <0.01) The difference of serum CYFRA21-1 level in PHC patients was also statistically significant (P <0.01). Conclusion Detection of serum levels of CYFRA21-1 has some guiding significance for the diagnosis of HPC.